Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 18, 2025Targeted OncologyOpen Access

Population Exposure–Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

HLHoi-Kei LonJHJennifer HibmaSJSibo Jiang

Discussion

Loading...

Member takes

Overview

Analysis shows elranatamab improves objective response rate in multiple myeloma patients, suggesting optimal dosing adjustments.

Key Points

  • Higher elranatamab exposure correlates with improved objective response in patients with multiple myeloma, indicating its efficacy.
  • The study observed a significant relationship between elranatamab levels and progression-free survival, highlighting its potential benefits.
  • Utilizing exposure-response analysis, assessments included logistic regression for response rates and Cox models for survival metrics.
  • These findings support the dosing regimen of elranatamab, emphasizing dosage adjustments for better patient outcomes.

Cite This Study

Lon et al. (2025) studied this question.

synapsesocial.com/papers/68af2edecf1dd9ea359e62c4https://doi.org/10.1007/s11523-025-01168-y
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Leveraging quantitative systems pharmacology modeling for elranatamab regimen optimization in relapsed or refractory multiple myeloma2025
  2. 2Elranatamab Fixed Dosing: A Safe, Effective, and Convenient Dosing Approach2025
  3. 3Real-world outcomes of elranatamab in relapsed/refreactor multiple myeloma: A single center analysis2025
  4. 4A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results2025 · 1 citations
  5. 5Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-32025